These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32948919)

  • 21. Histone Deacetylase 3 Inhibition Overcomes
    Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
    Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
    [No Abstract]   [Full Text] [Related]  

  • 22. Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
    Arai S; Takeuchi S; Fukuda K; Tanimoto A; Nishiyama A; Konishi H; Takagi A; Takahashi H; Ong ST; Yano S
    J Med Invest; 2020; 67(3.4):343-350. PubMed ID: 33148913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.
    Lv F; Sun L; Yang Q; Pan Z; Zhang Y
    Biomed Res Int; 2021; 2021():3621828. PubMed ID: 34722761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
    Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R
    Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis.
    Ma JY; Yan HJ; Gu W
    J Cancer Res Ther; 2015; 11(2):397-402. PubMed ID: 26148607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
    Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
    Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
    Ono T; Igawa S; Kurahayashi S; Okuma Y; Sugimoto A; Kusuhara S; Ozawa T; Fukui T; Sasaki J; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Naoki K
    Invest New Drugs; 2020 Jun; 38(3):885-893. PubMed ID: 32157598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
    J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
    Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ
    Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.
    Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Makino T; Otsuka H; Sano GO; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
    Cancer Genomics Proteomics; 2016 11-12; 13(6):475-482. PubMed ID: 27807070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
    Lau SC; Chooback N; Ho C; Melosky B
    Clin Lung Cancer; 2019 Sep; 20(5):e576-e583. PubMed ID: 31178389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
    Takeuchi S; Yoshimura K; Fujiwara T; Ando M; Shimizu S; Nagase K; Hasegawa Y; Takahashi T; Katakami N; Inoue A; Yano S
    J Med Invest; 2017; 64(3.4):321-325. PubMed ID: 28955007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
    Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.
    Yu X; Zhang X; Zhang Z; Lin Y; Wen Y; Chen Y; Wang W; Zhang L
    Cancer Commun (Lond); 2018 Jul; 38(1):51. PubMed ID: 30055651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
    Chevallier M; Tsantoulis P; Addeo A; Friedlaender A
    Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.